Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune responses to influenza, pneumococcal, and optional COVID-19 vaccination across adult age groups
NL-OMON54826Phase 4Completed
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Aug 2019
- Modality
- Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of influenza virus quadrivalent inactivated vaccine, pneumococcal 13-valent conjugate vaccine and mRNA COVID-19 vaccine in influenza, pneumococcal disease and coronavirus disease 2019 (COVID-19) (3 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Influenza and pneumococcal vaccine-specific serum antibody responses at 1 month. Started Aug 2019; status: completed.
02
Drugs
influenza virus quadrivalent inactivated vaccinepneumococcal 13-valent conjugate vaccinemRNA COVID-19 vaccine
03
Conditions
influenzapneumococcal diseasecoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON54826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54826.